To learn more about how to use this course, please watch the introductory video and/or download a one-page instructional pdf.


Interplay of Therapies of CVD and Diabetes Melitus

Review of the Interplay of CVD and T2DM Therapies
(0.50 CME/CNE/MOC credits)
Review of the interplay of Cardiovascular disease and T2DM therapies, with a focus on SDLT2 Inhibitors and GLP1 Agonists.

Effects of New Pharmaceutical Therapies in CVD Care
(0.50 CME/CNE/MOC credits)
Review of the 2018 guidance from the FDA and a focus on the effects of new pharmaceutical therapies in CVD care.

Perspectives on the Interplay of CVD and DM:
A Discussion Between Diabetic and Cardiovascular Experts

(0.50 CME/CNE/MOC credits)
Identify how to manage Type 2 diabetes using current strategies to reduce the burden of cardiovascular disease on high risk patients.

Guidelines and New/Emerging Clinical Trials

ACC CardiaCast: Emerging Data in SGLT2 Inhibitors
(0.25 CME/CNE/MOC credits)

Listen to the emerging data on SGLT2 Inhibitors, including a comprehensive review of types and application.

ACC CardiaCast: Emerging Data in GLP1 Agonists
(0.25 CME/CNE/MOC credits)
Listen to the emerging data on GLP1 agonists, including a comprehensive review of types and application.

Compare and Contrast the Use of SGLT2 Inhibitors and GLP1 Agonists: A Case Study
(0.50 CME/CNE/MOC credits)
Compare and contrast the use of SGLT2 Inhibitors and GLP1 Agonists when applied to a case-scenario.

ACC CardiaCast: Risk-Benefit Analysis and Dosing
(0.25 CME/CNE/MOC credits)
Identify the risk-benefits and effects of starting new diabetes therapies on a patient with Type 2 diabetes.

ACC CardiaCast: Intensifying and Altering Medical Therapies
(0.25 CME/CNE/MOC credits)
Identify the factors monitored for in Type 2 diabetes patients, including patient tolerance and benefit assessment, when intensifying and altering medical therapies.

Co-Morbidities and Cardio-Protective Properties

ACC CardiaCast: Examining DM Pharmacotherapy and CVD Comorbidities
(0.25 CME/CNE/MOC credits)
Identify the potential co-morbidities of Diabetes Mellitus pharmacotherapies.

ACC CardiaCast: The Cardio-Protective Nature of DM Pharmacotherapies
(0.25 CME/CNE/MOC credits)
Apply knowledge of the cardio-protective potential and co-morbidities of DM pharmacotherapy to solve a case-based scenario.

Cardio-Protective Properties of DM Pharmacotherapies: A Case Study
(0.25 CME/CNE/MOC credits)


Tailoring Treatment and Educating Patients

DM and CVD: Efforts in Cross-disciplinary Communication
(0.50 CME/CNE/MOC credits)
Identify the benefits and concerns of applying DM therapies to cardiovascular outcomes.

Educating Patients on T2DM Pharmacotherapies
(0.50 CME/CNE/MOC credits)
Identify the benefits and concerns of applying DM therapies to cardiovascular outcomes.

Patient Interactive: A Conversation With an Acute Patient
(0.50 CME/CNE/MOC credits)
Identify the benefits and concerns of applying DM therapies to cardiovascular outcomes.

Patient Interactive: A Conversation With a Chronic Patient
(0.50 CME/CNE/MOC credits)
Identify the benefits and concerns of applying DM therapies to cardiovascular outcomes.


Additional Resources and Information

Diabetes and Cardiometabolic Disease: Clinical Collection

Create an Account

CVD Prevention Guidelines: Diabetes Mellitus Management

Podcast Series Page

Faculty Information


This activity is supported by an educational grant from Novo Nordisk and Boehringer Ingelheim.